L3VLUP
ProSign in

BIIB · GILD in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

BIIBGILD
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • BIIB
  • GILD
010203040202120222023202420252026
Holders and value by quarter
QuarterBIIBGILD
Q3 202025 holders, $5.1bn25 holders, $14.2bn
Q4 202022 holders, $4.6bn27 holders, $13.4bn
Q1 202118 holders, $4.7bn24 holders, $14.5bn
Q2 202125 holders, $5.4bn18 holders, $14.9bn
Q3 202123 holders, $3.3bn20 holders, $16.4bn
Q4 202125 holders, $3.7bn20 holders, $16.8bn
Q1 202229 holders, $3.7bn28 holders, $13.2bn
Q2 202225 holders, $3.4bn26 holders, $13.6bn
Q3 202233 holders, $5.2bn24 holders, $13.3bn
Q4 202228 holders, $5.0bn32 holders, $21.1bn
Q1 202330 holders, $5.1bn27 holders, $21.8bn
Q2 202323 holders, $4.4bn24 holders, $20.7bn
Q3 202321 holders, $2.9bn24 holders, $20.0bn
Q4 202317 holders, $2.8bn22 holders, $21.5bn
Q1 202416 holders, $2.5bn30 holders, $20.3bn
Q2 202414 holders, $2.5bn28 holders, $18.5bn
Q3 202417 holders, $2.6bn29 holders, $24.2bn
Q4 202420 holders, $2.6bn28 holders, $25.9bn
Q1 202522 holders, $2.4bn33 holders, $32.0bn
Q2 202520 holders, $2.5bn27 holders, $30.9bn
Q3 202521 holders, $2.8bn23 holders, $29.4bn
Q4 202520 holders, $3.9bn25 holders, $34.3bn
Q1 202616 holders, $3.9bn25 holders, $38.5bn
Q2 202612 holders, $5.8bn26 holders, $34.2bn
BIIB

Biogen Inc

Holders
16
Reported value
$3.9bn
Buyers
13
Sellers
22

Breadth -9 among 91 comparable managers.

Pharmaceuticals and biotechnologyBiological productsHealthcare: biopharma and medtech · L3VLUP
GILD

Gilead Sciences Inc

Holders
25
Reported value
$38.5bn
Buyers
16
Sellers
21

Breadth -5 among 91 comparable managers.

Pharmaceuticals and biotechnologyBiological productsHealthcare: biopharma and medtech · L3VLUP

Who holds both, Q1 2026

Among the 31 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only BIIB (6)

Balyasny Asset Management LLC, ExodusPoint Capital Management LP, Glenview Capital Management LLC, PDT Partners LLC, Point72 Asset Management LP, Schonfeld Strategic Advisors LLC

Only GILD (15)

AllianceBernstein LP, Brevan Howard Capital Management LP, Bridgewater Associates LP, Capital Research Global Investors, Capital World Investors, Citadel Advisors LLC, Dodge & Cox, Holocene Advisors LP, Invesco Ltd, Janus Henderson Group Ltd, Millennium Management LLC, Neuberger Berman Group LLC, T. Rowe Price Associates Inc, Voloridge Investment Management LLC, Walleye Capital LLC

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →